AstraZeneca’s Imfinzi becomes first NHS immunotherapy for operable stomach cancer
Stomach cancer care gains immunotherapy, but NHS adoption now depends on surgery timing, toxicity management and recurrence data.
How AstraZeneca’s Owkin deal could push agentic AI deeper into drug development
Pharma has too much data and too little time. AstraZeneca’s Owkin deal tests whether agentic AI can sharpen drug development decisions.
Paradigm Health’s FDA collaboration puts clinical trial data automation under the spotlight
FDA review is moving closer to real time. Paradigm Health’s pilot with Amgen and AstraZeneca could reset clinical trial infrastructure.
Could Ampligen become a late-stage pancreatic cancer breakthrough after AIM ImmunoTech’s latest clinical push?
Can Ampligen’s Phase 3 push reshape pancreatic cancer treatment? Read how AIM ImmunoTech’s latest clinical progress could change the oncology outlook.
Can Lupin Limited gain ground in cardiometabolic generics with United States dapagliflozin launch?
Lupin Limited has launched generic dapagliflozin in the United States. Read what it means for Farxiga, pricing pressure, and market access.